Connor, Clark & Lunn Investment Management (CC&L)’s Altimmune ALT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,705	Closed	-$250K	–	1398
2024 Q3	$250K	Buy	40,705 +22,188	+120%	+$150K	﹤0.01%	1288
2024 Q2	$123K	Buy	+18,517	New	+$137K	﹤0.01%	1301
2023 Q4	–	Sell	-34,052	Closed	-$88.5K	–	1366
2023 Q3	$88.5K	Sell	34,052 -132,309	-80%	-$380K	﹤0.01%	1301
2023 Q2	$587K	Buy	166,361 +87,804	+112%	+$394K	﹤0.01%	945
2023 Q1	$332K	Buy	+78,557	New	+$933K	﹤0.01%	989
2022 Q4	–	Sell	-127,562	Closed	-$1.63M	–	1191
2022 Q3	$1.63M	Buy	+127,562	New	+$1.88M	0.01%	537
2021 Q4	–	Sell	-40,435	Closed	-$457K	–	1072
2021 Q3	$457K	Buy	+40,435	New	+$492K	﹤0.01%	788
2017 Q2	–	Sell	-294	Closed	-$72K	–	809
2017 Q1	$72K	Buy	+294	New	+$157K	﹤0.01%	864

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALT Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Altimmune (ALT) in Q4 2024, closing a stake of 40,705 shares — an estimated $250K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALT in Q1 2017 and held it in 8 quarters. The position peaked at $1.63M in Q3 2022. 182 funds tracked by Wall St. Rank hold ALT as of Q4 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Altimmune position as of Q4 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 40,705 Altimmune shares in Q4 2024, an estimated $250K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Altimmune in Q1 2017 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Altimmune position peaked at $1.63M in Q3 2022.
182 funds tracked by Wall St. Rank held Altimmune as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.